1. Rahimi K, Bidel Z, Nazarzadeh M, et al. Age-stratified and blood-pressure-stratified effects of blood-pressure-lowering pharmacotherapy for the prevention of cardiovascular disease and death: an individual participant-level data meta-analysis. Lancet. 2021;398(10305):1053–1064. https://doi.org/10.1016/S0140-6736(21)01921-8
2. Beckett NS, Peter R, Fletcher AE, Staessen JA, Liu L, Dumitrascu D, et al. HYVET Study Group. Treatment of hypertension in patients 80 years of age and older. N Engl J Med. 2008;358:1887–1898. https://doi.org/10.1056/NEJMoa0801369
3. Pajewski NM, Berlowitz DR, Bress AP, Callahan KE, Cheung AK, Fine LJ, et al. Intensive vs standard blood pressure control in adults 80 years or older: a secondary analysis of the systolic blood pressure intervention trial. J Am Geriatr Soc. 2020:68:496–504. https://doi.org/10.1111/jgs.16272
4. Zhang W, Zhang S, Deng Y, Wu S, Ren J, Sun G, et al. Trial of intensive blood-pressure control in older adults with hypertension. N Engl J Med. 2021;385:1268–1279. https://doi.org/10.1056/NEJMoa2111437
5. Гиляревский С. Р., Щедрина А.Ю., Ерусланова К.А., Кожевникова М.В., Лузина А.В., Готина А.Д. и др. Оценка безопасности достижения рекомендуемых целевых уровней артериального давления у пациентов пожилого и старческого возраста: протокол рандомизированного открытого проспективного прагматического исследования ПОРОГ (БезоПасность дОстижения РекОмендуемых целевых уровней артериального давления в Гериатрической практике). Артериальная гипертензия. 2025;31(1):47–53. https://doi.org/10.18705/1607-419X-2025-2401
6. United Nations. Department of Economic and Social Affairs. Population Division. World population prospects: the 2015 revision, key findings and advance tables. Working paper no. ESA/P/WP.241. New York (NY): United Nations; 2015.
7. O’Mahony D, Cherubini A, Guiteras AR, Denkinger M, Beuscart JB, Onde G, et al. STOPP/START criteria for potentially inappropriate prescribing in older people: version 3. Eur Geriatr Med. 2023;14(4):625–632. https://doi.org/10.1007/s41999-023-00777-y
8. Liau SJ, Zhao M, Hamada S, Gutiérrez-Valencia M, Jadczak AD, Li Li, et al. Deprescribing opportunities for frail residents of nursing homes: a multicenter study in Australia, China, Japan, and Spain. J Am Med Dir Assoc. 2024;25(5):876–883. https://doi.org/10.1016/j.jamda.2024.01.015
9. Mancia G, Kreutz R, Brunström M, Burnier M, Grassi G, Januszewicz A, et al. 2023 ESH Guidelines for the management of arterial hypertension the task force for the management of arterial hypertension of the European Society of hypertension endorsed by the European Renal Association (ERA) and the International Society of Hypertension (ISH). J Hypertension. 2023;41(12):1874–2071. https://doi.org/10.1097/hjh.00000000003480
10. Gnjidic D, Johansson M, Meng DM, Farrell B, LangfordA, Reeve E. Achieving sustainable healthcare through deprescribing. Cochrane Database Syst Rev. 2022;10(10):Ed000159. https://doi.org/10.1002/14651858
11. Sheppard JP, Burt J, Mark L, et al. Effect of antihypertensive medication reduction vs usual care on short-term blood pressure control in patients with hypertension aged 80 years and older: the OPTIMISE randomized clinical trial. JAMA. 2020;323(20):2039–2051. https://doi.org/10.1001/jama.2020.4871
12. Jing B, Liu X, Graham LA, Dave CV, Li Y, Fung K, et al. Deprescribing of antihypertensive medications and cognitive function in nursing home residents. JAMA Intern Med. 2024;184(11):1347–1355. https://doi.org/10.1001/jamainternmed.2024.4851
13. Silva IM, Moreira PM , Santos AM, Castro PR, Aguiar EC, Oliveira MG, et al. Deprescribing antihypertensives in older people in primary care: subgroup analysis of the MINOR randomised clinical trial. Int J Clin Pharm. 2025;47(1):53–59. https://doi.org/10.1007/s11096-024-01805-y
14. Odden MC, Graham LA, Liu X, Dave CV, Lee SJ, Li Yo, et al. Antihypertensive deprescribing and cardiovascular events among long-term care residents. JAMA Netw Open. 2024;7(11):e2446851. https://doi.org/10.1001/jamanetworkopen.2024.46851
15. Bogaerts J, Gussekloo J, Bianca EM, Le Cessie S, Mooijaart SP, van der Mast RC, at al. Effects of the discontinuation of antihypertensive treatment on neuropsychiatric symptoms and quality of life in nursing home residents with dementia (DANTON): a multicentre, open-label, blinded-outcome, randomised controlled trial. Age Ageing. 2024;53(7):afae133. https://doi.org/10.1093/ageing/afae133
16. Brunner L, Rodondi N, Aubert CE. Barriers and facilitators to deprescribing of cardiovascular medications: a systematic review. BMJ Open. 2022;12(12):e061686. https://doi.org/10.1136/bmjopen-2022-061686
17. Crutzen S, Baas G, Abou J, van den Born-Bondt T, Hugtenburg JG, Bouvy ML, et al. Barriers and enablers of older patients to deprescribing of cardiometabolic medication: a focus group study. Front Pharmacol. 2020;11:1268. https://doi.org/10.3389/fphar.2020.01268
18. Abou J, Crutzen S, Tromp V, Tromp V, Heringa M, Marum RV, Elders P, et al. Barriers and enablers of healthcare providers to deprescribe cardiometabolic medication in older patients: a focus group study. Drugs Aging. 2022;39(3):209–221. https://doi.org/10.1007/s40266-021-00918-7
19. Scott IA, Le Couteur DG. Physicians need to take the lead in deprescribing. Intern Med J. 2015;45:352–356. https://doi.org/10.1111/imj.12693
20. Archer L, Koshiaris C, Lay-Flurrie S, Snell KIE, Riley RD, Stevens R, et al. Development and external validation of a risk prediction model for falls in patients with an indication for antihypertensive treatment: retrospective cohort study. Br Med J (Clinical researched). 2022;379: e070918. https://doi.org/10.1136/bmj-2022-070918